Research programme: small molecules - Quoin Pharmaceuticals
Latest Information Update: 14 Mar 2023
At a glance
- Originator Quoin Pharmaceuticals
- Developer Queensland University of Technology; Quoin Pharmaceuticals
- Class Skin disorder therapies; Small molecules
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Scleroderma
Most Recent Events
- 08 Mar 2023 Quoin Pharmaceuticals plans a clinical trial for Scleroderma in Australia in the second half of 2023
- 23 May 2022 Quoin Pharmaceuticals and Queensland University of Technology agree to co-develop small molecules for Scleroderma
- 23 May 2022 Preclinical trials in Scleroderma in Australia (unspecified route), prior to May 2022